Earnings ·
Abbott Reports Q3 GAAP EPS of $0.53 and Adjusted EPS of $1.42 on $13.0B Sales
ABTAbbott Laboratories
Abbott Laboratories reported third-quarter 2026 results with total sales increasing 14.5 percent to $13,013 million and comparable sales growth of 7.0 percent. The company posted GAAP diluted earnings per share of $0.53, while adjusted diluted EPS excluding specified items reached $1.42. Abbott reaffirmed its full-year 2026 adjusted diluted EPS guidance range, tightening it to $5.50–$5.55 from the previous midpoint, and projected full-year comparable sales growth of approximately 6.0 percent. Additionally, the board declared a quarterly dividend of $0.63 per share, payable November 16, 2026, to shareholders of record as of October 15, 2026. Abbott operates in the global healthcare sector, developing and manufacturing medical devices, diagnostics, nutritionals, and branded generic medicines.